|
Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 18S ( Supplement), :
© 2010 American Society of Clinical Oncology
Efficacy results for progression-free survival
| PFS rate |
% of patients [95% CI]
|
| Chlorphenamine antihistamine n=122 |
Antihistamine other than chlorphenamine n=300 |
Any antihistamine plus corticosteroids n=700 |
Total antihistamine pre-medicated patients n=1122 |
|
| 12-week |
66 [58, 75] |
58 [52, 64] |
61 [57, 65] |
61 [58, 64] |
| 24-week |
32 [23, 40] |
32 [26, 37] |
35 [31, 39] |
34 [31, 37] |
| 36-week |
14 [7, 21] |
16 [12, 21] |
18 [15, 21] |
17 [14, 19] |
| 48-week |
5 [1, 9] |
6 [3, 9] |
6 [4, 8] |
6 [4, 8] |
|
PFS=progression-free survival
|
